The UK’s National Institute for Health and Care Excellence (NICE) has issued further draft guidance reaffirming its decision ...

NICE is seeking public comment on the updated draft guidances through March 27, with plans to issue final draft guidances in July.

Spread the love Table of Contents Introduction Methodology Top 10 Biotech Giants Rising Stars (11-25) Innovators and ...

Days after suffering a rejection in Australia, the Alzheimer’s drug hit another roadblock in the U.K., which found the drug ...

England’s National Institute for Health and Care Excellence (NICE) has given a second thumbs down to a pair of Alzheimer’s ...

A detailed review of a 6-month clinical trial further reinforces strong experimental evidence that a ketogenic diet may offer ...

NICE’s interim second draft guidance does not recommend lecanemab for use within the NHS in England and Wales at this time.

A new analysis provides substantial evidence that paramagnetic rim lesions drive disability in MS and are targetable with a ...

In a report released yesterday, William Pickering from Bernstein maintained a Hold rating on Biogen (BIIB – Research Report), with a price ...

In this edition of The Precedent, we outline the decision in Regeneron Pharms., Inc. v. Mylan Pharms. Inc. In Regeneron Pharms., Inc. v. Mylan ...